CRP and neoplasm: These factors, such as the activation of pro-inflammatory cytokines and elevated C-reactive protein (CRP) levels, along with a reduction in anti-inflammatory cytokines, can impair anti-tumor immunity and potentially influence the response to ICIs (33–35).